Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($1.78) per share and revenue of $1.1110 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 12:30 PM ET.

Corbus Pharmaceuticals Price Performance

NASDAQ:CRBP opened at $8.02 on Monday. Corbus Pharmaceuticals has a 52-week low of $4.64 and a 52-week high of $20.56. The stock has a fifty day simple moving average of $8.13 and a 200-day simple moving average of $10.54. The company has a market capitalization of $140.75 million, a PE ratio of -1.46 and a beta of 2.84.

Insider Activity

In other news, insider Dominic Smethurst sold 3,285 shares of Corbus Pharmaceuticals stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $8.09, for a total transaction of $26,575.65. Following the completion of the sale, the insider directly owned 95,887 shares in the company, valued at $775,725.83. The trade was a 3.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Cormorant Asset Management, Lp sold 30,029 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $11.46, for a total transaction of $344,132.34. Following the transaction, the insider directly owned 2,344,971 shares in the company, valued at $26,873,367.66. The trade was a 1.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 35,729 shares of company stock worth $390,245 over the last ninety days. 4.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter worth $573,000. Marshall Wace LLP acquired a new position in Corbus Pharmaceuticals in the second quarter valued at $137,000. Bank of America Corp DE lifted its position in Corbus Pharmaceuticals by 333.6% during the second quarter. Bank of America Corp DE now owns 71,893 shares of the biopharmaceutical company’s stock worth $496,000 after buying an additional 55,314 shares during the period. Vanguard Group Inc. boosted its stake in Corbus Pharmaceuticals by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock worth $7,742,000 after buying an additional 12,535 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in Corbus Pharmaceuticals in the 3rd quarter worth about $129,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Analyst Ratings Changes

CRBP has been the subject of a number of research reports. Royal Bank Of Canada cut their target price on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating for the company in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group upgraded Corbus Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Corbus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $44.38.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.